GLP-1
Dulaglutide
SaveA once-weekly GLP-1 receptor agonist (brand name Trulicity) FDA-approved for type 2 diabetes with demonstrated cardiovascular benefit in the REWIND outcomes trial.
Quick verdict
A well-established diabetes medication with cardiovascular benefit. Weight loss is moderate relative to semaglutide and tirzepatide.
Evidence score
A rough internal score reflecting quantity, quality, and consistency of human evidence. Not a clinical recommendation.
What the research shows
The AWARD Phase III program established glycemic efficacy across multiple comparators. REWIND demonstrated a reduction in major adverse cardiovascular events in a broad type 2 diabetes population. Weight loss averages 3–5 kg, less than semaglutide.
Benefits
- FDA-approved with extensive safety database
- Cardiovascular risk reduction (REWIND)
- Simple autoinjector with once-weekly dosing
Dosage notes
0.75 mg or 1.5 mg subcutaneously once weekly. Up to 4.5 mg for additional glycemic control.
Side effects
- Nausea
- Diarrhea
- Abdominal pain
- Decreased appetite
Who should be cautious
Contraindicated in personal or family history of medullary thyroid carcinoma or MEN2. GI side effects are common during titration.
What this page cannot tell you
Weight loss is less than newer GLP-1 RAs. Not FDA-approved specifically for obesity.
Leaderboard scores
- Weight loss55
Write a review
Sign in to write a review.